Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Cardiovascular and Metabolic Risk

Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes

  1. Kwan Yong Lee1,
  2. Byung-Hee Hwang2,
  3. Tae-Hoon Kim1,
  4. Chan Jun Kim3,
  5. Jin-Jin Kim2,
  6. Eun-Ho Choo3,
  7. Ik Jun Choi4,
  8. Young Choi1,
  9. Ha-Wook Park1,
  10. Yoon-Seok Koh1,
  11. Pum-Joon Kim1,
  12. Jong Min Lee3,
  13. Mi-Jeong Kim4,
  14. Doo Soo Jeon4,
  15. Jae-Hyoung Cho5,
  16. Jung Im Jung6,
  17. Ki-Bae Seung1 and
  18. Kiyuk Chang1⇑
  1. 1Cardiovascular Center and Cardiology Division, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  2. 2Cardiovascular Center and Cardiology Division, St. Paul’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  3. 3Cardiovascular Center and Cardiology Division, Uijeongbu St. Mary’s Hospital, The Catholic University of Korea, Uijeongbu, Republic of Korea
  4. 4Cardiovascular Center and Cardiology Division, Incheon St. Mary’s Hospital, The Catholic University of Korea, Incheon, Republic of Korea
  5. 5Division of Endocrinology, Department of Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  6. 6Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Republic of Korea
  1. Corresponding author: Kiyuk Chang, kiyuk{at}catholic.ac.kr.
Diabetes Care 2017 Sep; 40(9): 1241-1248. https://doi.org/10.2337/dc16-1844
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE We investigated the efficacy of coronary computed tomography angiography (CCTA) in predicting the long-term risks in asymptomatic patients with type 2 diabetes and compared it with traditional risk factors.

RESEARCH DESIGN AND METHODS We analyzed 933 patients with asymptomatic type 2 diabetes who underwent CCTA. Stenosis was considered obstructive (≥50%) in each coronary artery segment using CCTA. The extent and severity scores for coronary artery disease (CAD) were evaluated. The primary end point was major adverse cardiovascular events (MACE), including all-cause mortality, nonfatal myocardial infarction, and late coronary revascularization during a mean follow-up period of 5.5 ± 2.1 years.

RESULTS Ninety-four patients with MACE exhibited obstructive CAD with a greater extent and higher severity scores (P < 0.001 for all). After adjusting for confounding risk factors, obstructive CAD remained an independent predictor of MACE (hazard ratio 3.11 [95% CI 2.00–4.86]; P < 0.001]). The performance of a risk prediction model based on C-statistics was significantly improved (C-index 0.788 [95% CI 0.747–0.829]; P = 0.0349) upon the addition of a finding of obstructive CAD using CCTA to traditional risk factors, including age, male, hypertension, hyperlipidemia, smoking, estimated glomerular filtration rate, and HbA1c. Both integrated discrimination improvement (IDI) and net reclassification improvement (NRI) analyses further supported this finding (IDI 0.046 [95% CI 0.020–0.072], P < 0.001, and NRI 0.55 [95% CI 0.343–0.757], P < 0.001). In contrast, the risk prediction power of the coronary artery calcium score remained unimproved (C-index 0.740, P = 0.547).

CONCLUSIONS Based on our data, the addition of CCTA-detected obstructive CAD to models that include traditional risk factors improves the predictions of MACE in asymptomatic patients with type 2 diabetes.

Introduction

Recent guidelines recommend that type 2 diabetes mellitus (T2DM) be treated in a manner similar to coronary heart disease (1) since it is often accompanied by macrovascular complications according to large cohort studies (2). Patients with T2DM have a higher prevalence and extent of coronary atherosclerosis and higher rates of silent atherosclerotic lesions without ischemic symptoms than patients without T2DM (3,4). Therefore, the risk predictions are important, and clinicians should consider prophylactic measures even before patients show ischemic symptoms.

Coronary computed tomographic angiography (CCTA) is a noninvasive tool with good diagnostic performance in detecting obstructive coronary artery disease (CAD) (5). In previous reports from the FACTOR-64 study (6) and the DIAD (Detection of Ischemia in Asymptomatic Diabetics) study (7), noninvasive screening imaging tests, including CCTA and stress myocardial perfusion imaging, failed to reduce cardiovascular event rates in asymptomatic patients with T2DM. However, care should be taken in generalizing the results of the DIAD and FACTOR-64 studies across all ethnic populations or subgroups of high-risk patients.

A prior study (8) assessed the roles of associated major risk factors and demonstrated that exhibiting more than two risk factors was related to more severe forms of CAD and unfavorable coronary anatomy. Furthermore, as shown in recent case control studies (9–11), obstructive CAD, when detected using CCTA, is an independent predictor of composite major adverse cardiovascular events (MACE). However, only small numbers of asymptomatic patients with T2DM were enrolled for short-term follow-up periods. Thus, researchers have not clearly determined whether obstructive CAD detected by CCTA in asymptomatic patients with T2DM who are at high risk of the development of CAD may provide a clinically significant prognostic indicator. We enrolled asymptomatic patients with T2DM who are at high risk of the development of CAD and compared their long-term cardiovascular outcomes according to the extent and severity of CCTA-detected CAD to address this issue. We also evaluated the incremental value of CCTA-detected obstructive CAD compared with traditional risk factors in predicting long-term adverse clinical outcomes using traditional C-statistical and novel statistical metrics, including net reclassification improvement (NRI) and integrated discrimination improvement (IDI).

Research Design and Methods

Study Population

From January 2006 to December 2010, 933 asymptomatic patients with T2DM who were >30 years of age and had undergone CCTA were prospectively enrolled in the CRONOS-ADM (Coronary CT Angiography Evaluation for Clinical Outcomes in Asymptomatic Patients with Type 2 Diabetes Mellitus) registry to evaluate CCTA findings and the coronary artery calcium score (CACS) in the divisions of endocrinology and cardiology at two major cardiac centers in Korea (Seoul St. Mary’s Hospital, Seoul, Republic of Korea; and St. Vincent’s Hospital, Suwon, Republic of Korea). This registry included demographic characteristics; clinical, laboratory, CACS, and CCTA findings; and 7-year long-term clinical outcomes. A flowchart of the study population is depicted in Supplementary Fig. 1. A total of 390 patients refused to participate. A total of 67 patients were excluded for the following reasons: patients with type 1 diabetes, angina, or angina-equivalent symptoms according to the Rose questionnaire (12); patients receiving antiangina medications and patients who had a history of myocardial infarction (MI); and patients with previous coronary revascularization (either by percutaneous coronary intervention or bypass). Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 were also excluded. The diagnosis of T2DM was made using the 2010 criteria of the American Diabetes Association of fasting glucose ≥126 mg/dL, glycated hemoglobin (HbA1c) ≥6.5% or ≥48 mmol/mol, and/or postchallenge glucose (glucose at 2 h after a 75-g oral glucose load) ≥200 mg/dL (13). A more detailed description of this study population is presented in our recent articles (14,15). No corporation was involved in the design, performance, or analysis of the study. This prospective observational study was approved by the institutional review board of our institution and performed in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines (16). All patients provided written informed consent.

Scanning Protocol and Image Reconstruction

CCTA was performed using either a 64-slice multidetector computed tomography (MDCT) scanner (Light Speed VCT 64; GE Healthcare, Milwaukee, WI) or a dual-source computed tomography (DSCT) scanner (Somatom Definition; Siemens Healthcare, Forchheim, Germany). For the 64-slice MDCT scanning protocol, we used a slice collimation of 64 × 0.625 mm, a gantry rotation time of 350 ms, a pitch of 0.2, a tube voltage of 100–120 kV (depending on the patient’s BMI), and a tube current of 600 mA. For the DSCT scan protocol, slice collimation was performed at 2 × 32 × 0.6 mm using a z-flying focal spot, a gantry rotation time of 330 ms, a pitch of 0.2–0.5, a tube voltage of 100–120 kVp (depending on the patient’s BMI), and a reference tube current of 320 mA with an electrocardiogram-controlled tube current modulation. In each patient, 80 mL of the iodinated contrast agent iopromide (Ultravist 370; Schering AG, Berlin, Germany) or iomeprol (Iomeron 350; Bracco, Milano, Italy) was injected at a flow rate of 5 mL/s along with 50 mL of contrast mixture (15% contrast medium and 85% saline solution) at the same rate, which was controlled by bolus tracking in the ascending aorta (signal attenuation threshold 120 Hounsfield units [HU]). The scan delay was 7 s. In the absence of contraindications, each patient with a heart rate >80 bpm received an intravenous β-blocker, indenol or esmolol (Jeil Brevibloc; Jeil Pharma Co., Ltd., Seoul, Republic of Korea), 1 h before the scan, and a 0.3 mg sublingual dose of nitroglycerin was administered immediately before the scan. The estimated radiation dose ranged from 5 to 14 mSv. Images were reconstructed immediately after completing the scan and transferred to a computer workstation (MDCT: advantage Windows 4.3, GE Healthcare; DSCT: Syngo Multimodality Workplace, version 2008, Siemens Healthcare) for postprocessing, including axial and multiplanar reformatting, maximum intensity projection, and short-axis and cross-sectional views.

CCTA Analysis

All scans were analyzed by two radiologists with experience in interpreting several thousand CCTA scans. In accordance with the guidelines of the Society of Cardiovascular Computed Tomography, coronary segments were visually scored for the presence of coronary plaques using a 16-segment coronary artery model in an intent-to-diagnose manner (17). Segments were included in the analysis if the diameter was >1.5 mm. The severity of luminal diameter stenosis was scored as none (0% luminal stenosis), nonobstructive (plaques with a lumen narrowing <50%), obstructive (plaques with maximum stenosis ≥50%), or significantly obstructive (plaques with maximum stenosis ≥70%). CAD was diagnosed based on the maximum intraluminal stenosis in any of the segments of the major epicardial coronary arteries at the ≥50% stenosis threshold. Obstructive CAD in the branches of arteries was considered as corresponding to the major epicardial coronary arteries. The number of diseased vessels was assigned as one, two, three, or left main (LM) coronary artery vessels. The extent and severity of the CAD burden were measured using several CCTA scores (18,19). The CACS, atheroma burden obstructive score (ABOS), segment involvement score (SIS), and segment stenosis score (SSS) were included. CACS was assessed using dedicated software (Smartscore version 3.5, GE Healthcare; or Aquarius 3D Workstation, TeraRecon, San Mateo, CA). Coronary artery calcium levels were identified as the density exceeding the threshold of 130 HU (20). An overall Agatston score was recorded for each patient. The ABOS was defined as the number of plaques with >50% stenosis in the entire coronary artery tree. The SIS was calculated as the total number of coronary artery segments that exhibited plaques, regardless of the degree of luminal stenosis within each segment (minimum = 0; maximum = 16). The SSS was used to measure the overall extent of coronary artery plaques. Each individual coronary segment was graded as having no to severe plaques (i.e., scores from 0 to 3) based on the extent of obstruction of the luminal diameter of the coronary artery. The extent scores of all 16 individual segments were summed to yield a total score that could range from 0 to 48 (19). Plaques without any calcium were defined as noncalcified plaques (NCPs), and others were defined as mixed or calcified plaque (CPs), depending on consistency (using attenuation grade, i.e., mixed plaque ≤130 HU or CP >130 HU with an area ≥1.0 mm2, respectively) (20,21).

Study End Point and Follow-up

The primary end point was a composite of all-cause mortality, nonfatal MI, and late coronary revascularization (≥90 days). Late coronary revascularization was considered to be ischemia driven if the diameter of the stenotic lesion was ≥50%, according to a quantitative analysis of the electrocardiographic changes observed at rest or a positive functional study in the distribution of the target lesion, or ≥70% with recurrent symptoms at ≥90 days after stent implantation. All clinical outcomes of interest were confirmed by source documents and were centrally adjudicated by a clinical events committee at the Cardiovascular Center of Seoul St. Mary’s Hospital, which consisted of an independent group of clinicians whose members were unaware of the patient’s status. Information related to censored survival data (death or survival) and cause of death (cardiac or noncardiac death) was obtained from the Korean Office of Statistics with a unique personal identification number to validate the complete follow-up data.

Statistical Analysis

Baseline and biochemical characteristics were summarized as the means ± SD for continuous variables and as absolute numbers and percentages for discrete variables. Differences in continuous variables between groups were evaluated using unpaired t tests or Mann-Whitney rank sum tests. Differences in discrete variables between groups were analyzed using χ2 or Fisher exact tests. Cumulative event rates of CACS, CCTA-diagnosed obstructive CAD, ABOS, SIS, and SSS were calculated using a Kaplan-Meier estimator and compared using the log-rank statistic. A Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% CIs to describe the relationships between the various measures of CCTA-diagnosed CAD and composites of MACE, including all-cause mortality, nonfatal MI, and late revascularization. Each measure of CCTA-diagnosed CAD was adjusted for age, male sex, hypertension, hyperlipidemia, smoking, eGFR, and HbA1c and was analyzed using SPSS 20.0 (SPSS-PC Inc., Chicago, IL). Statistical significance was accepted at P < 0.05 using a two-tailed test.

The discriminative ability of the models was assessed using Harrell’s C-index, which is analogous to the area under the receiver operator characteristic curve and was applied to composite MACE data The IDI was used to express the absolute improvement in the mean discrimination slope and the probability of discrimination between the base model (model A) and the new models (models B to G), whereas the relative IDI illustrated the difference in the separation of MACE and nonevents over the separation in the base model. We selected the conventional risk model based on the risk factors included in the 10-year atherosclerotic cardiovascular disease risk algorithm, which was published in the 2013 American College of Cardiology/American Heart Association guidelines and referenced in the Framingham study (22–24). The risk factors were matched with the variables adjusted in the Cox regression model. Larger positive IDI and relative IDI values indicate greater improvements in model discrimination. Improvements in subject risk reclassification were further assessed using NRI and were applied to the MACE data. We computed the two versions of the NRI: a category-based and a category-free NRI. The category-based NRI followed typical categories used for determining MACE risk (determined after 1 year as <5%, 5% to <10%, and ≥20%). We used χ2 values and model Akaike information criterion (AIC) values as the parameters of model fit. The χ2 test, AIC, C-index, IDI, and NRI were analyzed using SAS version 9.4 (SAS Institute, Cary, NC).

Results

Patient Characteristics

Baseline characteristics, laboratory findings, and medication information are listed in Table 1. The mean age of the included patients was 63.4 ± 9.6 years, and the mean T2DM duration was 11.7 ± 9.3 years. The mean initial HbA1c level was 8.0 ± 1.9% (63.7 ± 21.1 mmol/mol). Our study population exhibited several comorbidities at baseline such as arterial hypertension, the presence of microalbuminuria, and diabetic retinopathy. Five hundred seven of 933 patients (54.3%) had arterial hypertension, 66 of 284 patients (23.24%) had microalbuminuria, and 217 of 433 patients (50.12%) had diabetic retinopathy. Although 55.6% of the patients were prescribed statins at the time of study enrollment, the mean lipid profile was within the normal range. During a mean follow-up period of 5.5 ± 2.1 years, 94 MACE occurred. Patients with MACE were older and had longer T2DM durations; they were more likely to be smokers and to have anemia, hyperglycemia, higher HbA1c, decreased eGFR, and a history of insulin treatment.

View this table:
  • View inline
  • View popup
Table 1

Baseline characteristics

Primary Outcomes

Among 94 MACE (10.1%), the number of patients who died of any cause, experienced nonfatal MI, or needed late coronary revascularization were 45 (4.8%), 5 (0.9%), and 49 (5.3%), respectively (Supplementary Table 1). According to CCTA, 40% (N = 374) of the study population had coronary artery obstruction of ≥50% and 11% (N = 45) had a significant obstruction lesion of ≥70%. Of the patients with normal CCTA findings (20.7%), there was only one cardiac death and no cases of nonfatal MI. In contrast, 63.8% of MACE occurred in patients with obstructive CAD detected using CCTA.

CCTA Findings and MACE

The CCTA findings are shown in Table 2. Among patients with adverse events, 12.8% had a normal coronary artery, 23.4% had nonobstructive CAD (<50%), 63.8% had obstructive CAD (≥50%), and 24.5% had ≥70% significant obstructive CAD. Normal or nonobstructive CAD seen on CCTA was not associated with an increased risk of MACE. On the other hand, obstructive CAD with three-vessel disease (3VD) or LM disease significantly contributed to the occurrence of MACE (P < 0.001), whereas patients with obstructive one-vessel disease (1VD) or two-vessel disease (2VD) were similarly distributed between the event group and the nonevent group. Patients with MACE were more likely to have higher ABOSs, SISs, SSSs (P < 0.001 for all), and CACSs (P = 0.012).

View this table:
  • View inline
  • View popup
Table 2

CCTA findings and calcium scores

CACS and Plaque Distribution

The mean CACS in the study population was 266.8 ± 530. The mean CACS of patients with MACE was 433.6 ± 648.5 (Table 2). The CACSs and plaque distributions are presented in Supplementary Table 2. A total of 231 (24.8%), 301 (32.3%), 194 (20.8%), and 166 (17.8%) patients had CACSs of 0, 0–100, 100–400, and >400, respectively. Contrary to our expectations, 12.8% of MACE occurred in patients with a CACS of 0. Even among patients with a CACS ≤100, 110 (11.9%) were found to have obstructive CAD on CCTA. CPs, NCPs, and mixed plaques were detected in 425 (35.7%), 389 (32.6%), and 378 (31.7%) patients, respectively. Among patients with NCPs, 53.2% were also found to have obstruction of >50% on CCTA.

Kaplan-Meier Curves

As noted in the Kaplan-Meier curves, patients with obstructive CAD had a significantly higher cumulative incidence of MACE than the normal and nonobstructed groups during a median follow-up period of 5.5 ± 2.1 years (P < 0.0001) (Supplementary Fig. 2A). Significant obstructive CAD was also associated with an 11-fold increase in the risk of composite MACE in these patients (P < 0.0001). Furthermore, a higher CACS was associated with a gradual increase in the incidence of MACE (P < 0.0001) (Supplementary Fig. 2B). Among patients with low calcium scores (CACS ≤100), obstructive CAD seen on CCTA was associated with a significantly increased risk of the development of composite MACE (21 [5%] vs. 15 [13.6%]; P < 0.001, log-rank test]). Patients with mixed plaques displayed a significantly worse survival rate than patients without plaques and patients with CPs or NCPs (Supplementary Fig. 2C) (P < 0.001, P < 0.001, and P = 0.022, respectively). Significant differences in event-free survival were not observed between patients with CPs and NCPs (P = 0.63). Supplementary Fig. 2D shows a positive relationship between the number of vessels with obstructive CAD and the risk of adverse events (all P < 0.001 compared with the reference). Significantly higher event rates were observed in patients with 3VD or LM disease compared with patients with 1VD or 2VD (P < 0.001 vs. 1VD, P = 0.011 vs. 2VD).

Risk Prediction

In the univariate Cox analysis, factors related to a greater risk of the primary outcome were old age, high HbA1c, a long T2DM duration, a history of insulin treatment, anemia, and low eGFR (Supplementary Table 3). Male sex and the presence of hypertension and hyperlipidemia showed a trend of increased HRs. More obstructive CAD; significant obstructive CAD; higher ABOSs, SISs, and SSSs on CCTA; and higher CACSs were identified as significant predictors of MACE (Table 3). The unadjusted HRs (95% CIs) in these patients were 4.45, 11.33, 6.07, 3.94, 5.43, and 1.28 (all P < 0.001), respectively. After adjusting for variables such as age, male sex, hypertension, hyperlipidemia, smoking, eGFR, HbA1c, CACS, and CCTA findings, the multivariate Cox proportional hazard analysis revealed that obstructive CAD, CACS, ABOS, SIS, SSS, and CACS were associated with increased occurrences of MACE during the 5-year follow-up period. The individually adjusted HRs for each of these factors were 3.83, 8.49, 5.07, 2.99, 4.52, and 1.21, respectively (P < 0.001 for all). Coronary obstruction >70% was associated with the largest increase in the risk of developing composite MACE.

View this table:
  • View inline
  • View popup
Table 3

Independent predictors of the primary outcome

Discrimination and Reclassification

Table 4 shows the incremental value of CCTA findings over conventional risk factors using conventional parameters of model fit (χ2 value and model AIC value) and model global performance (changes in C-statistic, IDI, and continuous NRI). Model A was the baseline, which consisted of conventional CAD risk factors such as age, male sex, hypertension, hyperlipidemia, smoking, eGFR, and HbA1c (C-index 0.716). The addition of obstructive CAD ≥50% (model B) significantly improved the predictive accuracy for discrimination (C-index 0.788 [95% CI 0.747–0.829], IDI 0.046 [95% CI 0.020–0.072]; P = 0.0349 and P = 0.0006, respectively). Moreover, model B was significantly better at predicting the probability of reclassification (NRI 0.550 [95% CI 0.343–0.757]; P < 0.0001). The inclusion of obstructive CAD ≥70% and ABOS also significantly improved the discrimination and reclassification power of the model (C-index 0.805 and 0.792, P = 0.0146 and 0.0258, respectively). However, adding the SIS, SSS, and CACS to risk model A did not improve its predictive value. Models E, F, and G had C-indexes of 0.756, 0.782, and 0.740, respectively (all P > 0.05). The inclusion of insulin treatment, the duration of diabetes, or hemoglobin level did not change the results in the multivariable Cox regression and discrimination models.

View this table:
  • View inline
  • View popup
Table 4

Effects of variables on the prediction accuracy and risk reclassification of each model (comparison of model A with other models)

Conclusions

In this study, the addition of CCTA-diagnosed obstructive CAD resulted in a significantly higher predictive power for MACE in asymptomatic patients with T2DM than the use of traditional risk factors alone during a long-term follow-up period of 5.5 years. The CACS failed to improve either the discrimination or reclassification power. Asymptomatic patients with T2DM and a greater coronary atherosclerotic burden on CCTA had a higher risk of MACE, and patients with MACE were more likely to have obstructive CAD and higher ABOSs, SISs, SSSs, and CACSs.

Current guidelines from the American Diabetes Association (25) state that routine screening of asymptomatic patients with T2DM is not recommended even for those with a high atherosclerotic cardiovascular risk, since CCTA screening did not significantly reduce composite MACE in asymptomatic patients with T2DM in the recent FACTOR-64 study (6). However, the FACTOR-64 study was not adequately powered, with a lower event rate (7.6%) than expected (16%), and the study population was exclusively Caucasian (6). Hence, the efficacy of routine CCTA screening in the actual high-risk asymptomatic T2DM population remains unclear. According to some studies, CCTA could be used more effectively in asymptomatic individuals with a higher risk of cardiac events, such as asymptomatic patients with a long T2DM duration or T2DM with microalbuminuria (6,14,15,26). Our study population showed high-risk characteristics, including a mean T2DM duration of 11.7 ± 9.3 years, a mean HbA1c of 8.0 ± 1.9% (63.7 ± 21.1 mmol/mol), and the presence of several comorbidities such as arterial hypertension (54.3%), microalbuminuria (23.24%), and diabetic retinopathy (50.12%). Over half (59.1%) of patients with microalbuminuria and 34.1% of patients with diabetic retinopathy had obstructive CAD seen on CCTA. Although these patients were initially asymptomatic, they had a 10.1% incidence of MACE during the 5.5-year follow-up period. A majority of the included patients (79%) had silent atherosclerotic lesions (both nonobstructive and obstructive) at baseline. Obstructive CAD was found in 40.1% of the patients, and significant obstructive CAD was found in 11.4% of the patients on CCTA, with 9.6% of patients having 3VD and 2.8% having LM disease, which were associated with poor prognostic outcomes. The long-term prognosis for patients with normal CCTA findings was favorable: only one cardiac death and no cases of nonfatal MI occurred. The high-risk features of asymptomatic individuals with T2DM and the longer follow-up period used in our study may have contributed to the usefulness of CCTA as a tool for predicting risk beyond the use of traditional risk factors alone, even after adjusting for a number of conventional CAD risk factors, including age, male sex, hypertension, hyperlipidemia, smoking, eGFR, and HbA1c. Prior studies (27,28) have focused on the use of CACS for predicting risk in asymptomatic patients with T2DM. According to a recent study (29) of 10,377 patients who were evaluated with CACS, patients with T2DM displayed a significantly higher risk of mortality than patients without T2DM across all CACS groups, including the 0 category of CACS. Some studies (29,30) have demonstrated that almost 40% of patients with diabetes had a CACS of 0 in their coronary arteries. In this cohort of asymptomatic T2DM patients, 12.8% of MACE occurred in patients in the 0 CACS category (Table 2). Based on these data, CACS alone is not sufficient for properly assessing risk and specifying lesions and vessels. Asymptomatic patients with T2DM, even patients without coronary calcification, should still be assessed with other risk prediction tools since calcification is only one component of coronary plaques. CCTA can be used to detect large calcifications and CPs as well as NCPs and spotty calcification. Recently, plaques with an NCP of <30 HU and spotty calcification were found to have a high positive predictive value for the development of an acute coronary syndrome occurrence (31). In our study, 32.6% of the plaques were detected as NCPs, which is consistent with recent findings from studies evaluating asymptomatic patients with T2DM using CCTA (32).

Limitations

This study has several limitations. First, patients were recruited from only two centers and the sample size was moderate. We have not validated our findings in different study populations. Second, the therapeutic plans regarding the coronary angiograms and/or percutaneous coronary interventions and medications after CCTA were not standardized to a specific protocol. Patients were treated at the discretion of each diabetologist and cardiologist in charge. Third, our asymptomatic T2DM population included patients with high-risk features such as the presence of microalbuminuria, diabetic retinopathy, a long T2DM duration of >10 years, and other comorbidities, which may have contributed to the comparatively higher number of MACE. Therefore, our findings on the ability of CCTA to predict risk cannot be generalized to all asymptomatic patients with T2DM. Further studies are needed to investigate the role of screening for CAD in specific subgroups of asymptomatic patients with T2DM.

Conclusion

In our study, asymptomatic patients with T2DM had a median T2DM duration of 11 years, a mean HbA1c of 8.0 ± 1.9% (63.7 ± 21.1 mmol/mol), and a 10.1% incidence of MACE. CCTA measurements of CAD prevalence, extent, and severity independently and incrementally predicted the occurrence of MACE in patients with T2DM without angina. In a subsequent discrimination and reclassification analysis, the addition of obstructive CAD detected using CCTA provided a significant increase in prognostic value compared with conventional risk factors alone, whereas the addition of CACS did not.

Article Information

Acknowledgments. The authors thank the Department of Biostatistics of the Catholic Research Coordinating Center for statistical consultations.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Author Contributions. K.Y.L. analyzed and interpreted the data and wrote the drafts of the manuscript. B.-H.H. and T.-H.K. contributed to the statistical analysis and the design of the study. C.J.K. guided the data analysis and interpretation processes. J.-J.K. contributed to the design and analysis of this study and the registry. E.-H.C. reviewed the final draft of the manuscript. I.J.C., Y.C., and H.-W.P. contributed to the discussion and data collection. Y.-S.K., P.-J.K., J.M.L., M.-J.K., D.S.J., J.-H.C., J.I.J., and K.-B.S. contributed to the drafting of the manuscript and critically revised it for important intellectual content. K.C. contributed to the design and analysis of this study and registry and reviewed the final draft of the manuscript. K.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc16-1844/-/DC1.

  • This article is featured in a podcast available at http://www.diabetesjournals.org/content/diabetes-core-update-podcasts.

  • Received August 27, 2016.
  • Accepted June 4, 2017.
  • © 2017 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Pignone M,
    2. Alberts MJ,
    3. Colwell JA, et al
    . Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121:2694–2701pmid:20508178
    OpenUrlFREE Full Text
  2. ↵
    1. UK Prospective Diabetes Study (UKPDS)
    . VIII. Study design, progress and performance. Diabetologia 1991;34:877–890pmid:1778353
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Andreini D,
    2. Pontone G,
    3. Bartorelli AL, et al
    . Comparison of the diagnostic performance of 64-slice computed tomography coronary angiography in diabetic and non-diabetic patients with suspected coronary artery disease. Cardiovasc Diabetol 2010;9:80pmid:21114858
    OpenUrlPubMed
  4. ↵
    1. Zellweger MJ,
    2. Hachamovitch R,
    3. Kang X, et al
    . Prognostic relevance of symptoms versus objective evidence of coronary artery disease in diabetic patients. Eur Heart J 2004;25:543–550pmid:15120050
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Schuijf JD,
    2. Pundziute G,
    3. Jukema JW, et al
    . Diagnostic accuracy of 64-slice multislice computed tomography in the noninvasive evaluation of significant coronary artery disease. Am J Cardiol 2006;98:145–148pmid:16828582
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Muhlestein JB,
    2. Lappé DL,
    3. Lima JA, et al
    . Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA 2014;312:2234–2243pmid:25402757
    OpenUrlCrossRefPubMed
  7. ↵
    1. Young LH,
    2. Wackers FJ,
    3. Chyun DA, et al.; DIAD Investigators
    . Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547–1555pmid:19366774
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Scognamiglio R,
    2. Negut C,
    3. Ramondo A,
    4. Tiengo A,
    5. Avogaro A
    . Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 2006;47:65–71pmid:16386666
    OpenUrlFREE Full Text
  9. ↵
    1. Faustino A,
    2. Providência R,
    3. Mota P, et al
    . Can cardiac computed tomography predict cardiovascular events in asymptomatic type-2 diabetics? Results of a long term follow-up. BMC Cardiovasc Disord 2014;14:2pmid:24400648
    OpenUrlPubMed
    1. van den Hoogen IJ,
    2. de Graaf MA,
    3. Roos CJ, et al
    . Prognostic value of coronary computed tomography angiography in diabetic patients without chest pain syndrome. J Nucl Cardiol 2016;23:24–36pmid:26156098
    OpenUrlPubMed
  10. ↵
    1. Min JK,
    2. Labounty TM,
    3. Gomez MJ, et al
    . Incremental prognostic value of coronary computed tomographic angiography over coronary artery calcium score for risk prediction of major adverse cardiac events in asymptomatic diabetic individuals. Atherosclerosis 2014;232:298–304pmid:24468142
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rose G,
    2. McCartney P,
    3. Reid DD
    . Self-administration of a questionnaire on chest pain and intermittent claudication. Br J Prev Soc Med 1977;31:42–48pmid:856370
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. American Diabetes Association
    . Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33(Suppl. 1):S62–S69pmid:20042775
    OpenUrlFREE Full Text
  13. ↵
    1. Kim JJ,
    2. Hwang BH,
    3. Choi IJ, et al
    . Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by coronary CT angiography. Eur Heart J Cardiovasc Imaging 2015;16:1065–1073pmid:26069244
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kim JJ,
    2. Hwang BH,
    3. Choi IJ, et al
    . A prospective two-center study on the associations between microalbuminuria, coronary atherosclerosis and long-term clinical outcome in asymptomatic patients with type 2 diabetes mellitus: evaluation by coronary CT angiography. Int J Cardiovasc Imaging 2015;31:193–203pmid:25281423
    OpenUrlPubMed
  15. ↵
    1. Vandenbroucke JP,
    2. von Elm E,
    3. Altman DG, et al.; STROBE Initiative
    . Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:805–835pmid:18049195
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Raff GL,
    2. Abidov A,
    3. Achenbach S, et al.; Society of Cardiovascular Computed Tomography
    . SCCT guidelines for the interpretation and reporting of coronary computed tomographic angiography. J Cardiovasc Comput Tomogr 2009;3:122–136pmid:19272853
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hadamitzky M,
    2. Hein F,
    3. Meyer T, et al
    . Prognostic value of coronary computed tomographic angiography in diabetic patients without known coronary artery disease. Diabetes Care 2010;33:1358–1363pmid:20200300
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Min JK,
    2. Shaw LJ,
    3. Devereux RB, et al
    . Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol 2007;50:1161–1170pmid:17868808
    OpenUrlFREE Full Text
  19. ↵
    1. Agatston AS,
    2. Janowitz WR,
    3. Hildner FJ,
    4. Zusmer NR,
    5. Viamonte M Jr,
    6. Detrano R
    . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–832pmid:2407762
    OpenUrlFREE Full Text
  20. ↵
    1. Leber AW,
    2. Becker A,
    3. Knez A, et al
    . Accuracy of 64-slice computed tomography to classify and quantify plaque volumes in the proximal coronary system: a comparative study using intravascular ultrasound. J Am Coll Cardiol 2006;47:672–677pmid:16458154
    OpenUrlFREE Full Text
  21. ↵
    1. Goff DC Jr,
    2. Lloyd-Jones DM,
    3. Bennett G, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    . 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(Suppl. 2):S49–S73pmid:24222018
    OpenUrlFREE Full Text
    1. Kannel WB,
    2. McGee DL
    . Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979;2:120–126pmid:520114
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Wong ND,
    2. Zhao Y,
    3. Patel R, et al
    . Cardiovascular risk factor targets and cardiovascular disease event risk in diabetes: a pooling project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study. Diabetes Care 2016;39:668–676pmid:27208374
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Giugliano D,
    2. Maiorino MI,
    3. Bellastella G,
    4. Esposito K
    . Comment on American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In Standards of Medical Care in Diabetes—2016. Diabetes Care 2016;39(Suppl. 1):S52–S59 (Letter). Diabetes Care 2016;39(Suppl. 1):e86–e87. https://doi.org/10.2337/dc15-2829pmid:27222559
    OpenUrlFREE Full Text
  24. ↵
    1. Celeng C,
    2. Maurovich-Horvat P,
    3. Ghoshhajra BB,
    4. Merkely B,
    5. Leiner T,
    6. Takx RA
    . Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis. Diabetes Care 2016;39:1274–1280pmid:27330128
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Polonsky TS,
    2. McClelland RL,
    3. Jorgensen NW, et al
    . Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA 2010;303:1610–1616pmid:20424251
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Budoff MJ,
    2. Shaw LJ,
    3. Liu ST, et al
    . Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol 2007;49:1860–1870pmid:17481445
    OpenUrlFREE Full Text
  27. ↵
    1. Raggi P,
    2. Shaw LJ,
    3. Berman DS,
    4. Callister TQ
    . Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004;43:1663–1669pmid:15120828
    OpenUrlFREE Full Text
  28. ↵
    1. Anand DV,
    2. Lim E,
    3. Darko D, et al
    . Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 2007;50:2218–2225pmid:18061069
    OpenUrlFREE Full Text
  29. ↵
    1. Motoyama S,
    2. Sarai M,
    3. Harigaya H, et al
    . Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009;54:49–57pmid:19555840
    OpenUrlFREE Full Text
  30. ↵
    1. Park GM,
    2. Lee SW,
    3. Cho YR, et al
    . Coronary computed tomographic angiographic findings in asymptomatic patients with type 2 diabetes mellitus. Am J Cardiol 2014;113:765–771pmid:24528613
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes Care: 40 (9)

In this Issue

September 2017, 40(9)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes
Kwan Yong Lee, Byung-Hee Hwang, Tae-Hoon Kim, Chan Jun Kim, Jin-Jin Kim, Eun-Ho Choo, Ik Jun Choi, Young Choi, Ha-Wook Park, Yoon-Seok Koh, Pum-Joon Kim, Jong Min Lee, Mi-Jeong Kim, Doo Soo Jeon, Jae-Hyoung Cho, Jung Im Jung, Ki-Bae Seung, Kiyuk Chang
Diabetes Care Sep 2017, 40 (9) 1241-1248; DOI: 10.2337/dc16-1844

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Computed Tomography Angiography Images of Coronary Artery Stenosis Provide a Better Prediction of Risk Than Traditional Risk Factors in Asymptomatic Individuals With Type 2 Diabetes: A Long-term Study of Clinical Outcomes
Kwan Yong Lee, Byung-Hee Hwang, Tae-Hoon Kim, Chan Jun Kim, Jin-Jin Kim, Eun-Ho Choo, Ik Jun Choi, Young Choi, Ha-Wook Park, Yoon-Seok Koh, Pum-Joon Kim, Jong Min Lee, Mi-Jeong Kim, Doo Soo Jeon, Jae-Hyoung Cho, Jung Im Jung, Ki-Bae Seung, Kiyuk Chang
Diabetes Care Sep 2017, 40 (9) 1241-1248; DOI: 10.2337/dc16-1844
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Research Design and Methods
    • Results
    • Conclusions
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Impact of Obesity on Measures of Cardiovascular and Kidney Health in Youth With Type 1 Diabetes as Compared With Youth With Type 2 Diabetes
  • Serum Galectin-3 and Subsequent Risk of Coronary Heart Disease in Subjects With Childhood-Onset Type 1 Diabetes: A Cohort Study
  • OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function
Show more Cardiovascular and Metabolic Risk

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.